Sailong Pharmaceutical Group Co., Ltd. (002898) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sailong Pharmaceutical Group Co., Ltd.

Why is Sailong Pharmaceutical Group Co., Ltd. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 3.07% and Operating profit at -198.97% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

The company has declared negative results for the last 4 consecutive quarters

The company has declared negative results in Jun 24 after 2 consecutive negative quarters
NET PROFIT(HY) At CNY -30.49 MM has Grown at -560.34%
OPERATING CASH FLOW(Y) Lowest at CNY -29.27 MM
NET SALES(Q) At CNY 53.05 MM has Fallen at -17.91%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 19.10%, its profits have fallen by -810.6%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sailong Pharmaceutical Group Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sailong Pharmaceutical Group Co., Ltd.

24.02%

0.95

51.12%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.07%

EBIT Growth (5y)

-198.97%

EBIT to Interest (avg)

-3.13

Debt to EBITDA (avg)

9.10

Net Debt to Equity (avg)

0.31

Sales to Capital Employed (avg)

0.42

Tax Ratio

6.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.41%

ROE (avg)

0.16%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.77

EV to EBIT

-23.82

EV to EBITDA

-117.82

EV to Capital Employed

1.58

EV to Sales

4.27

PEG Ratio

Dividend Yield

ROCE (Latest)

-6.65%

ROE (Latest)

-10.25%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -50.76% (YoY

PRE-TAX PROFIT(Q)

At CNY -1.09 MM has Grown at 87.57%

NET PROFIT(Q)

At CNY -1.04 MM has Grown at 87.47%

-32What is not working for the Company

NET PROFIT(HY)

At CNY -30.49 MM has Grown at -560.34%

OPERATING CASH FLOW(Y)

Lowest at CNY -29.27 MM

NET SALES(Q)

At CNY 53.05 MM has Fallen at -17.91%

INTEREST(HY)

At CNY 3.5 MM has Grown at 7.54%

ROCE(HY)

Lowest at -6.91%

CASH AND EQV(HY)

Lowest at CNY 81.82 MM

DEBT-EQUITY RATIO (HY)

Highest at 32.09 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.9%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.4%

Here's what is working for Sailong Pharmaceutical Group Co., Ltd.

Pre-Tax Profit

At CNY -1.09 MM has Grown at 87.57%

over average net sales of the previous four periods of CNY -8.73 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -1.04 MM has Grown at 87.47%

over average net sales of the previous four periods of CNY -8.29 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Raw Material Cost

Fallen by -50.76% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sailong Pharmaceutical Group Co., Ltd.

Net Sales

At CNY 53.05 MM has Fallen at -17.91%

over average net sales of the previous four periods of CNY 64.63 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY -29.27 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 3.5 MM has Grown at 7.54%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Cash and Eqv

Lowest at CNY 81.82 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 32.09 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.9%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.4%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio